

Fig. 15. Distributions of the number of edges of Voronoi polygons for epidermal Langerhans cells and three geometrical models*. CONTROL: untreated. TACROLIMUS: every posterior auricle was treated with 0.1% tacrolimus ointment (Protopic[®] Ointment 0.1%) once a day for 3 weeks.




Fig. 16. Tests for the densities and spatial regularities of epidermal Langerhans cells. CONTROL: untreated. TACROLIMUS: every posterior auricle was treated with 0.1% tacrolimus ointment (Protopic[®] Ointment 0.1%) once a day for 3 weeks. NS*: by the Kruskal-Wallis test. $p < 0.05^{**}$: by the Mann-Whitney U test.




Fig. 17. The estimated potential functions of epidermal Langerhans cells. CONTROL: untreated. TACROLIMUS: every posterior auricle was treated with 0.1% tacrolimus ointment (Protopic[®] Ointment 0.1%) once a day for 3 weeks. The estimated model functions were very similar between-groups. However the chart shows that some diameters in the tacrolimus group became large.